news, journals and articles from all over the world.
Dr. Tanya Stoyanova, associate professor of molecular and medical pharmacology and urology at the David Geffen School of Medicine at UCLA(Link is external) (Link opens in new window), was awarded a $1.8 million grant from the National Cancer Institute to identify new drivers and test new therapeutic strategies for advanced treatment-resistant prostate cancer.
The funding helps further the team’s work in improving the quality of life for men diagnosed with prostate cancer by predicting and preventing significant long-term side effects from radiation treatment.
The Harvey L. Neiman Health Policy Institute announces the public launch of a new online tool that reveals the overlap between cancer disparities and social determinants of health (SDOH) using advanced heat maps of U.S. counties. The Cancer Equity Compass can identify high-opportunity targets for policies and programs to achieve equitable health outcomes in underserved populations.
A cost-effectiveness analysis found that screening for prostate cancer using biparametric magnetic resonance imaging (bpMRI) as a first-line approach is less cost-effective than first-line prostate-specific antigen (PSA) testing with second-line multiparametric MRI (mpMRI).
For this presentation at ASCO 2024, please email the media contact for more information.
A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.
A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy and Johns Hopkins Drug Discovery.
Follow-on analysis of results from the phase 3 PSMAfore study, along with the overall study results, support the consideration of 177Lu-PSMA-617 as a new standard treatment approach for this prevalent population of patients with mCRPC. Research led by Dana-Farber Cancer Institute and others.
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Physician-scientists from the Department of Urology at Cedars-Sinai will be attending the American Urological Association (AUA) Annual Meeting May 3-6 in San Antonio, Texas, and are available to discuss the latest research and innovations in urological care.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.
Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone.
Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access to care among patients with metastatic castration-sensitive prostate cancer (mCSPC) since the first novel hormonal therapy was approved in 2018.
NIBIB-supported researchers have developed a smart nanoprobe designed to infiltrate prostate tumors and send back a signal using an optical imaging technique known as Raman spectroscopy.
Microvascular function is lower in Black men following a recent diagnosis of prostate cancer, compared to white men.
Annual prostate cancer cases worldwide are projected to double by the year 2040, and annual deaths are projected to increase by 85% – mainly among men in low- and middle-income countries. A commissioned report in The Lancet seeks to guide cancer experts worldwide on how to manage this massive influx of prostate cancer patients.
Desai Sethi Urology Institute (DSUI) Scientific Director Nima Sharifi, M.D., authored an invited commentary in JAMA Network Open related to a new Million Veteran Program study on the HSD3B1 genotype, an allele he helped discover more than 10 years ago.
Moncrief Cancer Institute debuted its new Mobile Screening Clinic prior to the Tarrant County Commissioners Court meeting today. The $1 million, 36-foot cancer screening clinic was funded by Tarrant County through a three-year, $9 million grant awarded to Moncrief Cancer Institute in 2022. Part of the federal funding Tarrant County received through the American Rescue Plan Act (ARPA), the grant enabled Moncrief to expand its comprehensive cancer screening program to more underserved residents in Tarrant County.
Former Tulane University researcher Dr. Andrew Schally has donated his Nobel Prize to Tulane’s School of Medicine. Schally won the award in 1977 for identifying the presence of key peptides in the hypothalamus and successfully synthesizing them, research that led to advanced prostate cancer treatment methods.
Sandalwood oil has been used worldwide for centuries. Now, a study is the first to demonstrate in vivo the chemo-preventive properties of a by-product of the oil in a mouse model. Results show administering alpha-santalol reduced visible prostate tumors, protected the normal tissue, and delayed progression from a precancerous condition to a high-grade form of cancer. These findings are significant because mortality in prostate cancer patients is mainly attributable to advanced stages of the disease.
Recent news of two high-profile people has brought awareness to prostate health. Effecting men between ages 45 to 69, when detected early, prostate cancer has the best chance for successful treatment. Aditya Bagrodia, MD, urologic oncologist with UC San Diego…
For Black men with prostate cancer, racial representation is a key factor affecting trust in websites offering information on prostate cancer, reports a study in the March issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
New prostate screening guidelines organized by the Prostate Cancer Foundation aim to address the longstanding health disparity in prostate cancer: Black men are diagnosed with and die from prostate cancer at a much higher rate than white men.
A new prostate cancer resource – the Prostate Cancer Outcomes Report Card – hopes to make it easier for men and their families to better understand the treatment options and outcomes.
It may be possible to restore drug-resistant neuroendocrine prostate cancer to a state that responds to treatment by depletion of a certain protein in cancer cells.
Pancreatic cancer can be a devastating diagnosis due to its extremely aggressive nature and low survival rate.
Renowned urologists from leading academic centers shared their insights and clinical recommendations at Urology on the Beach, a three-day professional conference hosted by the Desai Sethi Urology Institute (DSUI) at the University of Miami Miller School of Medicine.
Findings indicate the importance of earlier and more frequent prostate cancer screening for Black men.
The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.
People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.
Desai Sethi Urology Institute at the University of Miami Miller School of Medicine will host its second annual, in-person Urology on the Beach meeting, January 19 to 21, 2024, at the Fontainebleau Hotel in Miami Beach.
The American Society for Radiation Oncology (ASTRO) today announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.
Tissue-sparing treatments using focal therapy, aimed to avoid side effects like urinary incontinence, are becoming available for prostate cancer patients like Morton McPhail of Texas.
UCSF Health has performed 150 robotic focal high-intensity focused ultrasound (HIFU) procedures for patients living with prostate cancer, becoming the first on the west coast and the first UC Health System to reach that milestone.
Experts in cell signalling at the Babraham Institute have identified how prostate cancer cells achieve cell growth free from the usual growth cues and regulators.
The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.
The American College of Surgeons (ACS) has partnered with the American Urological Association (AUA) to share vital information about the concerning rise in advanced cases of prostate cancer and how men can protect their health and make the most informed decisions about their healthcare.
David M. Golombos, MD, addresses prostate cancer topics
Findings from the newly published study in The Journal of Clinical Investigation suggest a large proportion of men have testosterone concentrations that are much higher in and around the prostate than traditional blood draws suggest. And this elevated exposure near the prostate increases the risk of poor outcomes after surgical removal of the prostate gland.
Renowned prostate cancer researcher Dr. Lorelei Mucci is the director of strategic research partnerships at the American Cancer Society. Her role includes leading an ACS initiative called IMPACT, or “Improving Mortality Toward Prostate Cancer Together” to address the alarming negative trends in prostate cancer incidence and disparities. For Prostate Cancer Awareness Month Dr. Mucci reviews the signs and symptoms of prostate cancer, including important information about risk factors, PSA screening, and more.
A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient’s long-term overall survival.
In June 2021, Bob McCarrick and his wife Stacey headed out to Los Angeles to enroll in the MIRAGE trial and start radiation therapy.
New research shows blood cancers are often misdiagnosed, an NCI grant to develop a urine test for prostate cancer, a surgeon-scientist receives Sylvester’s first DoD grant to study pancreatic cancer, bolstering emergency preparedness for climate-driven disasters, and more are included in this month’s tip sheet .
To explore prostate cancer disparities, researchers looked to another disorder, diabetes. They conducted a clinical trial and report four biomarkers linked to a higher risk of metastatic prostate cancer in men of West African heritage. They will present their results at ACS Fall 2023.
Benjamin N. Breyer, MD, MAS, FACS, a renowned leader in urology and urological surgery, has been appointed chair of the UCSF Department of Urology. Breyer is a urologic surgeon who is internationally known for performing complex urethral and penile reconstruction for urethra stricture and cosmetic disfigurement, male incontinence, male fistula, and surgery for erectile dysfunction.
Prostate cancer is resistant to one of the most powerful chemotherapy medications — cisplatin. Now, researchers in ACS Central Science have developed the first therapy of its kind that disrupts prostate cancer cells’ metabolism and releases cisplatin into the weakened cells, causing them to die.
Researchers at Sylvester Comprehensive Cancer Center have developed a first-of-its-kind, orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells. The compound – Platin-L – works in two ways, breaking down a process that malignant prostate cancer cells use to fuel their growth, and delivering cisplatin directly into treatment-resistant cancer cells.
Data from a new study published in NEJM Evidence shows promise for personalized use of short term ADT in men with predominantly intermediate-risk prostate cancer. The information validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.
A new study shows that an artificial intelligence (AI) model co-developed by researchers in the UCLA Jonsson Comprehensive Cancer Center and department of Urology at UCLA can help doctors determine the extent of cancer within the prostate.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu